| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D221-20 |
| filingDate |
2000-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08f449f136070859418ff6cecadb4347
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb4b5e2d97738be6b7b688e36f15bb74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff50a158bd330421df1314c742438372
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07de9837bf46f2f8380749341be52e4f |
| publicationDate |
2001-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GB-2355457-A |
| titleOfInvention |
Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
| abstract |
Novel spirotricyclic substituted azacycloalkane derivatives of the formula shown in claim 1 and their pharmaceutically acceptable salts have been found to exhibit activity against benign prostatic hyperplasia (BPH). Compounds of this kind are selective in their ability to relax smooth muscle tissue enriched in the alpha 1 a receptor subtype without simultaneously inducing hypotension. Such tissue is found surrounding the urethral lining. Thus treatment with the said compounds offers relief to males suffering from BPH by permitting less hindered urine flow. The said derivatives may also be used in conjunction with human 5-alpha reductase inhibitor compounds in the treatment of both acute and chronic BPH. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11584883-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018009861-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155714-B2 |
| priorityDate |
1999-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |